CTLA4 and melanoma: IDO1 has also been reported to participate in a resistance mechanism to checkpoint inhibitors, and the combination of CTLA-4 blockade and an IDO1 inhibitor resulted in more effective antitumor immunity in a melanoma mouse model [13].